Ticker: NVAX

Company Overview: Novavax, Inc. (NASDAQ: NVAX) is a biotechnology company specializing in innovative vaccine development. With a focus on global health challenges, Novavax aims to leverage its proprietary technology platforms to advance vaccines for various infectious diseases. Recent Development...

Novavax, Inc. (NASDAQ: NVAX) has reported significant financial growth in its latest quarterly earnings for the period ended March 31, 2025. Key Highlights Total Revenue: $666.7 million, a substantial increase from $93.9 million in Q1 2024. Net Income: $518.6 million compared to a net loss of $1...

Novavax's stock soared after announcing a lucrative $1.2 billion licensing agreement with Sanofi for its COVID-19 vaccines, significantly boosting its valuation and providing a robust financial lifeline.

Dow, S&P 500, and Nasdaq gain on economic optimism. Gold prices rebound, while Novavax secures a pivotal deal with Sanofi. Oil prices also rise.